A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer

Inclusion Criteria: * Male or female, aged 18 to 75 years old; * The Karnofsky Performance Scale (KPS) score \>=80; * Adenocarcinoma of stomach and gastroesophageal junction (Siewert II/III) diagnosed pathologically; * clinical T3-4a/N+/M0 (The 8th edition of the American Joint Committee on Cancer (AJCC) staging system); * According to the Response Evaluation Criteria In Solid Tumours (RECIST) 1.1 standard, there is at least one evaluable lesion in the abdominal CT/MRI; * The surgeons participating in this study judged the lesion to be resectable; * Physical condition allows the surgery; Exclusion Criteria: * Distant metastasis or local unresectable factors; * Cytotoxic chemotherapy, radiotherapy, immunotherapy or radical surgery for the treatment of this gastric cancer, except for corticosteroids; * Active autoimmune diseases or a history of autoimmune diseases; * History of malignant tumors within 2 years; * Gastrointestinal bleeding within two weeks prior to enrollment, or those with high bleeding risk; * Gastrointestinal perforation and/or fistula occurred within 6 months before enrollment; * Upper gastrointestinal obstruction or abnormal physiological function or suffering from malabsorption syndrome, which may affect the absorption of drugs; * Weight loss \>=20% within 2 months before enrollment; * A history of the following lung diseases: interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, etc.; * Uncontrollable systemic diseases including diabetes, hypertension, etc.; Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis, HIV infection, etc.; * Untreated patients with chronic hepatitis B or chronic HBV carriers with hepatitis B virus (HBV) DNA exceeding 500 IU/mL, or hepatitis C virus (HCV) RNA positive patients should be excluded; * Any of the following cardiovascular risk factors (refer to Research Guide); * Known peripheral nerve disease \>=NCI CTCAE Grade 1. However, patients with only the disappearance of the deep tendon reflex (DTR) need not be excluded; * Moderate or severe renal damage \[creatinine clearance equal to or lower than 50 ml/min (calculated according to the Cockcroft and Gault equation)\], or serum creatinine\> upper limit of normal (ULN); People with known dihydropyrimidine dehydrogenase (DPD) deficiency; * Those who are allergic to any research drug ingredients; * Underwent major surgery within 28 days prior to enrollment;